Literature DB >> 33299163

Psychedelics re-engineered for potential use in the clinic.

Gabriela Manzano-Nieves, Conor Liston.   

Abstract

Keywords:  Drug discovery; Neuroscience

Year:  2021        PMID： 33299163     DOI： 10.1038/d41586-020-03404-z

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

Review 1.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.

Authors:  Franz X Vollenweider; Michael Kometer
Journal:  Nat Rev Neurosci       Date:  2010-08-18       Impact factor: 34.870

2.  Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.

Authors:  Geoffrey E Noller; Chris M Frampton; Berra Yazar-Klosinski
Journal:  Am J Drug Alcohol Abuse       Date:  2017-04-12       Impact factor: 3.829

Review 3.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

4.  Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Authors:  Dao-Yao He; Nancy N H McGough; Ajay Ravindranathan; Jerome Jeanblanc; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

5.  Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum.

Authors:  S D Glick; M E Kuehne; J Raucci; T E Wilson; D Larson; R W Keller; J N Carlson
Journal:  Brain Res       Date:  1994-09-19       Impact factor: 3.252

6.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

7.  Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Authors:  Stephen Ross; Anthony Bossis; Jeffrey Guss; Gabrielle Agin-Liebes; Tara Malone; Barry Cohen; Sarah E Mennenga; Alexander Belser; Krystallia Kalliontzi; James Babb; Zhe Su; Patricia Corby; Brian L Schmidt
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

8.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.

Authors:  Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt
Journal:  Lancet Psychiatry       Date:  2016-05-17       Impact factor: 27.083

Review 9.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

10.  Psychedelics Promote Structural and Functional Neural Plasticity.

Authors:  Calvin Ly; Alexandra C Greb; Lindsay P Cameron; Jonathan M Wong; Eden V Barragan; Paige C Wilson; Kyle F Burbach; Sina Soltanzadeh Zarandi; Alexander Sood; Michael R Paddy; Whitney C Duim; Megan Y Dennis; A Kimberley McAllister; Kassandra M Ori-McKenney; John A Gray; David E Olson
Journal:  Cell Rep       Date:  2018-06-12       Impact factor: 9.423
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.